Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogs are used for the treatment of type 2 diabetes. GLP-1 displays antiinflammatory and surfactant-releasing effects. Thus, we hypothesize that treatment with GLP-1 analogs will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with a measurement of enhanced pause in a whole-body plethysmograph. mRNA levels of GLP-1R, surfactants (SFTPs), and a number of inflammatory markers were measured. GLP-1R was highly expressed in lung tissue. Mice treated with GLP-1R agonists had a noticeably better clinical appearance than the control group. Enhanced pause increased dramatically at day 17 in all control mice, but the increase was significantly less in the groups of GLP-1R agonist-treated mice (P < .001). Survival proportions were significantly increased in GLP-1R agonist-treated mice (P < .01). SFTPB and SFTPA were down-regulated and the expression of inflammatory cytokines were increased in mice with obstructive lung disease, but levels were largely unaffected by GLP-1R agonist treatment. These results show that GLP-1R agonists have potential therapeutic potential in the treatment of obstructive pulmonary diseases, such as chronic obstructive pulmonary disease, by decreasing the severity of acute exacerbations. The mechanism of action does not seem to be the modulation of inflammation and SFTP expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Lung Function Impairment and Metabolic Syndrome
Leone, N., Courbon, D., Thomas, F., Bean, K., Jégo, B., Leynaert, B., Guize, L., & Zureik, M. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200807-1195oc · Cited by 531
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
Apicella, M., Campopiano, M. C., Mantuano, M., Mazoni, L., Coppelli, A., & Del Prato, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30238-2 · Cited by 903
Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Drucker, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa011 · Cited by 399
Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238
“Beyond local gut effects, rising GLP-1 levels during gut ischemia may exert protective effects on heart (Drucker, 2016), kidney (Skov, 2014), lung (Viby et al., 2013), and liver (Wang et al., 2014).”
BackgroundGLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000847 · Cited by 111
“Interestingly, liraglutide has in rodents been shown to protect against airway infections.(52) The potential importance of GLP-1R agonist–mediated mucin upregulation was supported by the concomitant upregulation of the glucosaminyl (N-acetyl) transferase 1 (GCNT1) in the Brunner’s glands.”
Background
Metadata
- Authors
- Viby, N.-E., Isidor, M. S., Buggeskov, K. B., Poulsen, S. S., Hansen, J. B., & Kissow, H.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-12-01
- Volume
- 154
- Issue
- 12
- Pages
- 4503-4511
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2137713697
- Cited by
- 133
- References
- 12
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice. https://app.cochat.ai/papers/10.1210/en.2013-1666
- The paper
- Viby, N.-E., Isidor, M. S., Buggeskov, K. B., Poulsen, S. S., Hansen, J. B., & Kissow, H. (2013). Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice. Endocrinology. https://doi.org/10.1210/en.2013-1666
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.